Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
about
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayTGF-β signaling and its targeting for glioma treatmentWNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration.Role of Nitric Oxide in Glioblastoma Therapy: Another Step to Resolve the Terrible Puzzle ?The roles of TGFβ in the tumour microenvironment.Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.The interconnectedness of cancer cell signaling.LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.Recent developments on immunotherapy for brain cancer.Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.Aligned chitosan-polycaprolactone polyblend nanofibers promote the migration of glioblastoma cells.Cancer subclonal genetic architecture as a key to personalized medicine.Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor.Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma.Novel approaches to glioma drug design and drug screening.Transforming growth factor-beta and its implication in the malignancy of gliomas.Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.New tricks for an old fox: impact of TGFβ on the DNA damage response and genomic stability.Molecular targets in glioblastoma.Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.Transforming growth factor-β: A therapeutic target for cancer.Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationTargeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas.Induction of transient tenogenic phenotype of high-density cultured human dermal fibroblasts.
P2860
Q26797238-15B9920E-EA27-437E-988D-66EEFA6D0CD2Q28082042-DC706F90-DBBC-4B8A-B263-213E9B1BB26BQ30572906-A1A625E0-499E-46F4-A6DA-EED708587BF6Q33361853-55A3E4E5-D298-4824-ADE2-28C6326E9A16Q33630845-DC468CBB-12EB-4D4B-BB87-87AA7ABB0643Q33912275-E2A3356D-F438-42E3-BC8B-FC02E803DB16Q35289038-370B96E6-B9CD-4036-80C4-6C8F0A1D87E3Q35669733-CBC01715-E9A2-4FA6-85FC-B814471F50BCQ35854002-7E8F7D91-6A7E-46FC-9B0B-AF9EBB281462Q35992355-0495F372-9A82-4CCE-9449-7AC44287214BQ36511945-DF730F40-E9D2-4263-BEFD-5E070F38DBBCQ37048061-3958DEF6-D144-4A9F-BB88-2CEB1E0A60CAQ37384592-084B60C7-8A25-4634-B706-7A566F462A5DQ37448116-4934A28C-7650-49F5-BA31-75839432047EQ37503365-E1DD3B19-35FE-4B33-9214-88BB2BF6182AQ37615676-7ABAFAC2-19C4-42D5-9809-7380A2FAA057Q37699420-F0F1DE13-F6DE-43D3-9D82-AFEE25AE5D08Q38112184-3A96DDCB-6349-4B4F-B0A9-7A8BF02E5EEFQ38192972-CB95C155-21BE-4930-8E8A-1CFA47E17AC5Q38227496-7DAA664B-6A94-4F35-BB70-D226837E6CFCQ38245806-84A91A4F-EC47-4E43-88FA-B92BA3A2E921Q38465854-FF14D17E-C095-4E81-9ABE-55EF1E09C11CQ38957729-CFD33228-D9EA-4FCE-B591-99DBA0106CF6Q39071510-5E6E7AE4-8CA8-4868-8622-03B83398E7C7Q39346505-BCB932D6-F2D4-484F-9F29-52E01A2D963FQ41474996-B9614781-C5DE-4832-889F-D3088449B1A6Q41879186-59C73B84-BCD5-465B-90FB-099F585FA231Q44705929-473ED620-CD27-4D21-80C0-8A87AE3AF0FCQ47996105-DA13D92C-BA7A-4A98-B401-08309ACAB22BQ48089996-2747F2CB-B7B9-41F6-8913-742DD913A679Q52657971-433D3408-75C4-4A1D-9D4C-2C952D7AA7CE
P2860
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.
@en
type
label
Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.
@en
prefLabel
Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.
@en
P2093
P2860
P356
P1433
P1476
Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.
@en
P2093
Carmen Timke
Kai Hauser
Klaus J Weber
Mengxian Zhang
Michael Lahn
Peter E Huber
Peter Peschke
Tobias W Herion
Ute Wirkner
P2860
P304
P356
10.1593/NEO.11258
P577
2011-06-01T00:00:00Z